Clinical Trial Search

Primary: Proportion of Patients With no Fluid on OCT at Week 24

Primary: The Percentage of Patients With Less Than 15 Letters of ETDRS Visual Loss at 12 Months. — 22; 14 percentage of participants

Primary: The Number of Patients With no Fluid on OCT — 10 participants

Primary: Mean Visual Acuity Change — 5.6; 5.8 ETDRS letters

Primary: Mean Change in Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score — 7.2 letters

Primary: Mean Change in Central 1 mm Subfield Thickness Between Baseline and 9 Months — -51; -60 millimeters

Primary: Reduction in Macular Edema — 15; 8; 4 Participants

Primary: Mean Change From Baseline in Visual Acuity — 1.8; 1.0 ETDRS letters

Primary: Mean Central Subfield Thickness (CST) — 422.9; 419.7; 364.5; 346.7 microns

Primary: Injection Free Interval — 34; 29 Days

Primary: Mean Change in Visual Acuity (VA) From Baseline at Month 6 — 6.1; 2.0 ETDRS Letters

Primary: Change From Baseline in Central Retinal Thickness as Measured by Optical Coherence Tomography (OCT) at Week 4 — 360.9; -62.0 Microns

Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 12 — 6.8; 8.5; 8.8…

Primary: Mean Change in Visual Acuity Letter Score — 2.7; 3.0 Letter Score

Primary: Mean Change in Visual Acuity — 15.0; 5.6 letters — p=0.02

Primary: Efficacy of Treatment Outcomes by Change in Visual Acuity From Baseline — 69.95; 74 letters

Primary: Change in Edema From Baseline to Month 6 Central Subfield Thickness ) on Heidelberg Optical Coherence Topography — -30.0; 7.5 microns

Primary: Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Week 52 — 0.4; 0.5; 1.7 Scores on a scale — p=<0.0001

Primary: Mean Number of Retreatments (Day 0 Excluded) — 3.97; 3.00; 4.05; 5.39 number of retreatments

Primary: Development of PDR and/or DME (Whichever Came First) — 27; 75 Eyes

Primary: Visual Acuity - Continuous — -6.1; -1.6; 2.4 Letters seen

Primary: Number of Subjects With Positive LUCENTIS® Retreatment Status at Day 84 — 25; 25 Participants

Primary: Proportion of Subjects Who Gain Two or More Lines in Best Corrected Visual Acuity(BCVA) Score in the Study Eye Compared With Baseline. — 3; 18 participants

Primary: Visual Acuity: Percentage of Patients Losing 3 or More Lines(15 Letters) of Visual Acuity From Baseline. — 80; 90 percent of participants

Primary: Mean Change of CR/LT From Baseline at Week 12 — -153.5; -75.6; -169.2; -56.3 μm

Primary: Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment of Diabetic Retinopathy Study (ETDRS) Letter Scores From Baseline to Week 52 - Last…

Primary: Change in BCVA as Measured by the ETDRS Letter Score — -2.1; -0.4 Letters correctly read — p=0.0162

Primary: Change in Central Subfield Retinal Thickness (CSRT) From Baseline to Day 90. — 384.00; 318.00; -30.75 micrometer — p=<0.0001

Primary: Change in Central Subfield Thickness on OCT From Baseline to Week 36 — -54; -.1 microns

Primary: Vision — 0.16 logMAR